ESTRO 2025 - Abstract Book

S4194

RTT - Patient experience and quality of life

ESTRO 2025

Material/Methods: We conducted a single-institution study focusing on patient-reported outcome measures. We compared the results from various EORTC QoL scales at three points: baseline (M0), at the conclusion of treatment (M1), and four months post-treatment (M4). Higher scores on functional scales indicate better functioning. Minimal Important Differences (MID) were categorized as small (5-10 points), moderate (10-20 points), and large (over 20 points), while clinically significant differences were considered to be above 10 points. Results: A preliminary analysis was conducted after enrolling 150 patients. Out of these, 118 patients who received treatment for PC between 2022 and 2023 completed all three questionnaires. The global health status at the peak of toxicity (post-radiotherapy, M1) was recorded at 67.16, compared to a baseline of 80.36, with recovery to baseline levels at M4 (79.66). The baseline emotional functioning score was 76.41, which increased to 82.06 at M1 and further improved to 87.5 at M4. The baseline score for social functioning was 94.91, dropping to 78.24 at M1 and recovering to 93.92 at M4. When examining the two components of social functioning separately, we observed a more significant decline in the social dimension (M0: 94.92 vs. M1: 75.98) compared to the familiar dimension (M0: 94.92 vs. M1: 80.51